Background/Aims: A large amount of new data on the treatment of chronic hepatitis B has
become available such that the 2003 consensus statement requires revision and update …

Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B evolves in the natural history of
chronic hepatitis B virus (HBV) infection linked with selection of nonproducing HBeAg but …

In the last years, marked progress has been made in the treatment of chronic hepatitis B.
The efficacy of lamivudine, the first nucleoside analogue available, is limited by the high …

We have previously demonstrated that combination peginterferon and lamivudine treatment
has superior antiviral efficacy to lamivudine monotherapy in chronic hepatitis B. In this study …

Nucleoside analogue therapy allows safe, long-term suppression of hepatitis B virus (HBV)
and is a major milestone in the treatment of chronic hepatitis B. Entecavir has recently been …

Background. Chronic hepatitis B infection carries considerable risk for the development of
cirrhosis and hepatocellular carcinoma. Treatment options are increasing but are limited to …

Background Currently, more and more nucleos (t) ide analogs are appearing as therapeutic
options in the treatment of chronic hepatitis B (CHB). Their efficacy and safety profile in …

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and
congresses. The data in the following tables has been retrieved from the Clinical Trials …

Adefovir dipivoxil (Hepsera®, Gilead Sciences) is a prodrug of adefovir, with potent antiviral
activity against hepatitis B virus. Adefovir dipivoxil therapy, 10 mg daily for 48 weeks, is …

In the past decade, substantial advances have been made in the treatment of chronic
hepatitis B. Approved treatments include interferon-α, the nucleoside analog inhibitor …